Erstad, DerekTager, Andrew M.Hoshida, YujinFuchs, Bryan2018-04-192017Erstad, Derek J., Andrew M. Tager, Yujin Hoshida, and Bryan C. Fuchs. 2017. “The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer.” Molecular & Cellular Oncology 4 (3): e1311827. doi:10.1080/23723556.2017.1311827. http://dx.doi.org/10.1080/23723556.2017.1311827.http://nrs.harvard.edu/urn-3:HUL.InstRepos:35982000ABSTRACT Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.en-USATXchemopreventioncirrhosisfibrosisHCChepatocellular carcinomaLPALPAR1NASHnon-alcoholic steatohepatitisJournal Article2018-04-1910.1080/23723556.2017.1311827